REGENXBIO Inc.
World Rank (Jan-05-2024)
10,026
Market Cap (Jan-05-2024)
0.765 Billion USD
World Rank (Jul-30-2023)
9,791
Market Cap (Jul-30-2023)
0.818 Billion USD
World Rank (Dec-25-2022)
8,565
Market Cap (Dec-25-2022)
0.963 Billion USD
World Rank (Jan-07-2022)
8,285
Market Cap (Jan-07-2022)
1.25 Billion USD
Annual Revenue in USD
112 Million USD
Annual Net Income in USD
-280 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Company Profile
REGENXBIO is a Clinical Stage Biotechnology company. The company currently developing gene therapy product candidates for the treatment of retinal, metabolic and neurodegenerative diseases and provide long lasting effects, potentially significantly altering the course of disease and delivering improved patient outcomes. The headquarters is in USA.
Company Website